Susan L Baldwin

Summary

Affiliation: Infectious Disease Research Institute
Country: USA

Publications

  1. pmc Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:3063-71. 2009
  2. doi request reprint Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
  3. doi request reprint Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
  4. pmc Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
    Mark T Orr
    Infectious Disease Research Institute, Seattle 98104, USA
    J Control Release 172:190-200. 2013
  5. pmc Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98102, USA
    J Immunol 191:2514-25. 2013
  6. pmc Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Infect Dis 207:1242-52. 2013
  7. pmc The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
  8. pmc Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
  9. pmc Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
  10. doi request reprint Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Influenza Other Respir Viruses 7:815-26. 2013

Collaborators

Detail Information

Publications19

  1. pmc Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:3063-71. 2009
    ..This highlights the need to explore different routes of immunization based on the adjuvant formulations used...
  2. doi request reprint Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
    ....
  3. doi request reprint Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
    ..Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model...
  4. pmc Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
    Mark T Orr
    Infectious Disease Research Institute, Seattle 98104, USA
    J Control Release 172:190-200. 2013
    ..These results demonstrate that there are multiple solutions for an effective formulation of a novel TB vaccine candidate that enhances both TH1 generation and protective efficacy. ..
  5. pmc Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98102, USA
    J Immunol 191:2514-25. 2013
    ..Our findings provide insight into the development of vaccines not only for tuberculosis, but other diseases requiring T cell immunity. ..
  6. pmc Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Infect Dis 207:1242-52. 2013
    ....
  7. pmc The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
    ..These results highlight the importance of properly formulating subunit vaccines with effective adjuvants for use against tuberculosis...
  8. pmc Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  9. pmc Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
    ....
  10. doi request reprint Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Influenza Other Respir Viruses 7:815-26. 2013
    ..However, few reports have been published that systematically evaluate the in vitro stability and in vivo adjuvant effects of different emulsion components...
  11. doi request reprint Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses
    Anthony L Desbien
    Infectious Disease Research Institute, Seattle, WA
    Biotechniques 54:345-8. 2013
    ..We are advancing this technology as a platform for rapid, simple, high-throughput assessment of homologous and heterologous antibody responses to influenza disease and vaccination...
  12. pmc Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 19:1633-40. 2012
    ..Emulsion dose titration in the absence of formulated GLA caused some reduction in humoral and cellular immune responses compared to those with the 2% squalene emulsion dose...
  13. pmc Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
    ....
  14. pmc Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
    ....
  15. pmc Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay
    Lance K Ching
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    J Immunol Methods 373:54-62. 2011
    ..Overall, the QuantiGene platform is reliable, reproducible, and sensitive. These agonists have the potential to be used as adjuvant components in vaccines against various pathogens...
  16. pmc A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    Sci Transl Med 2:53ra74. 2010
    ....
  17. pmc A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 5:e13677. 2010
    ..These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines...
  18. doi request reprint Clinical vaccine development for H5N1 influenza
    Christopher H Clegg
    TRIA Bioscience Corp, Suite 250, 1616 Eastlake Avenue East, Seattle, WA 98102, USA
    Expert Rev Vaccines 12:767-77. 2013
    ..In this article, the authors review the efforts spent in developing an effective vaccine for H5N1 influenza and summarize clinical studies that highlight the progress made to date. ..
  19. pmc Adjuvant solution for pandemic influenza vaccine production
    Christopher H Clegg
    TRIA Bioscience Corp, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 109:17585-90. 2012
    ..Innate signaling pathways that amplify priming of Th1 CD4 T cells will likely improve vaccine performance against future outbreaks of lethal pandemic flu...